Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or non-pregnant, non-lactating female, age 2 to 35 years, inclusive as of the day of the Screening Visit.~* Clinical diagnosis of Lennox-Gastaut syndrome, where seizures that result in drops are not completely controlled by current antiepileptic treatments.~* Onset of seizures at 11 years of age or younger.~* Abnormal cognitive development.~* Must be receiving at least 1 concomitant AED and up to 4 concomitant anti-epileptic treatments.~Key Exclusion Criteria:~* Etiology of seizures is a degenerative neurological disease.~* History of hemiclonic seizures in the first year of life.~* Subject only has drop seizures in clusters, where individual seizures cannot be counted reliably.~* Pulmonary arterial hypertension.~* Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke.~* Receiving concomitant therapy with: centrally-acting anorectic agents; monoamineoxidase inhibitors; any centrally-acting compound with clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; atomoxetine, or other centrally-acting noradrenergic agonist; cyproheptadine.~* Taking felbamate for less than 1 year prior to screening and/or does not have stable liver function and hematology laboratory tests, and/or the dose has not been stable for at least 60 days prior to the Screening Visit.~* Currently receiving an investigational product.~* Institutionalized in a general nursing home (ie, in a facility that does not specialize in epilepsy care).~* A clinically significant condition, or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to the Screening Visit, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- ZX008 0.2 or 0.8 mg/kg/day (Type: EXPERIMENTAL): Part 1: ZX008 is supplied as an oral solution. Subjects will be randomized to receive 1 of 2 doses of ZX008 0.2 mg/kg/day or 0.8 mg/kg/day.
- Matching Placebo (Type: PLACEBO_COMPARATOR): Part 1: Matching ZX008 placebo is supplied as an oral solution.
- Open-Label (Type: EXPERIMENTAL): Part 2: ZX008 is supplied as an oral solution. Study medication will be administered twice a day (BID) in equally divided doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).